Oncology · Combination TherapyRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 12:31:47 AM

Assessment confidence: 85% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for OPDUALAG is a significant regulatory milestone that could strengthen Bristol Myers Squibb's competitive position in oncology. This development necessitates close monitoring of the approval timeline and market dynamics as it may influence competitive strategies in combination therapies. Regulatory context from FDA (FDA AP — OPDUALAG (SUPPL)) supports the near-term read. Assessment grounded in 29 ranked evidence items (26 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market entry and competitive dynamics related to OPDUALAG's approval. The strongest clinical anchor is A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (bristol myers squibb). In Oncology · Combination Therapy, 8 regulatory and 6 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma (Bristol Myers Squibb) — entity match (bristol myers squibb). Secondary pressure from FDA Accepts Supplement Application for YERVOY (ipilimumab).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — OPDUALAG (SUPPL) (FDA). Entity match (bristol myers squibb).

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, OPDUALAG could capture market share in the oncology sector, impacting revenue streams for Bristol Myers Squibb and potentially altering competitive dynamics with other oncology therapies.
Upside for Bristol Myers Squibb may improve if A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Bristol Myers Squibb may improve if Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. (PubMed) delivers favorable follow-through.
Upside for Bristol Myers Squibb may improve if CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (ClinicalTrials.gov) delivers favorable follow-through.
Bristol Myers Squibb document relevant to the signal.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's final decision and any upcoming data presentations related to OPDUALAG.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — OPDUALAG (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — OPDIVO (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Investigational New Drug (IND) Application
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
FDA AP — OPDIVO QVANTIG (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA Accepts Supplement Application for YERVOY (ipilimumab)
Humanexa Signalshigh relevance
Entity match (bristol myers squibb)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypert
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
NK cell-based immunotherapy.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
OPDUALAG

Commercial impact

medium

If approved, OPDUALAG could capture market share in the oncology sector, impacting revenue streams for Bristol Myers Squibb and potentially altering competitive dynamics with other oncology therapies.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive step towards potential approval, but the final decision from the FDA will ultimately determine the product's market readiness and compliance requirements.

What to watch

Monitor the timeline for the FDA's final decision and any upcoming data presentations related to OPDUALAG.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.